Stock TERN TERNS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Market Closed - Nasdaq
Other stock markets
 04:00:02 2024-05-31 pm EDT 		5-day change 1st Jan Change
6.035 USD -14.03% Intraday chart for Terns Pharmaceuticals, Inc. +0.58% -7.01%
May. 13 Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 08 Terns Pharmaceuticals, Inc. Announces Executive Changes CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
TERNS PHARMACEUTICALS TO PARTICIPATE IN UBS OBESITY THERAPEUTICS DAY
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
Terns Pharmaceuticals : Corporate Presentation May 2024
Terns Pharmaceuticals Announces Leadership Changes
Terns Pharmaceuticals Announces Leadership Changes
Terns Pharmaceuticals, Inc. Announces Executive Changes
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
TERNS PHARMACEUTICALS REPORTS INDUCEMENT GRANT TO NEW EMPLOYEE UNDER NASDAQ LISTING RULE 5635(4)
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals : Corporate Presentation April 2024
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer
UBS Trims Terns Pharmaceuticals Price Target to $18 From $19, Maintains Buy Rating
North American Morning Briefing : Stocks Struggle After New Records
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TERN Stock
  4. News Terns Pharmaceuticals, Inc.
  5. Other languages